Epirus Biopharmaceuticals Inc  

(Public, NASDAQ:EPRS)   Watch this stock  
0.486
+0.026 (5.68%)
Jun 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.45 - 0.51
52 week 0.45 - 8.75
Open 0.49
Vol / Avg. 1.01M/1.20M
Mkt cap 11.25M
P/E     -
Div/yield     -
EPS -2.53
Shares 26.18M
Beta 2.72
Inst. own 61%
May 13, 2016
Q1 2016 EPIRUS Biopharmaceuticals Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -2025.65% -7444.79%
Operating margin -1993.40% -7315.83%
EBITD margin - -7375.61%
Return on average assets -97.67% -84.42%
Return on average equity -208.66% -151.78%
Employees 73 -
CDP Score - -

Address

699 Boylston St Ste 8
BOSTON, MA 02116-2836
United States - Map
+1-617-6003497 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company's products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.

Officers and directors

Mark H. N. Corrigan M.D. Chairman of the Board, Director
Age: 58
Bio & Compensation  - Reuters
Michael Wyand Ph.D. President, Chief Operating Officer
Age: 59
Bio & Compensation  - Reuters
Scott M. Rocklage Ph.D. Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Thomas A. Shea Chief Financial Officer, Senior Vice President, Treasurer
Age: 46
Bio & Compensation  - Reuters
Robert Ticktin Senior Vice President, General Counsel, Secretary
Age: 53
Bio & Compensation  - Reuters
Vincent E. Aurentz Chief Business Officer
Bio & Compensation  - Reuters
Daotian Fu Ph.D. Director
Age: 52
Bio & Compensation  - Reuters
J. Kevin Buchi Independent Director
Age: 59
Bio & Compensation  - Reuters
Geoffrey M. Duyk M.D., Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
William L. Hunter M.D. Independent Director
Age: 52
Bio & Compensation  - Reuters